Quote:
Originally posted by Say_hello_for_me
Re: 2. Did the regulators take the position that the drugs won't be allowed at all in their jurisdictions, or just that the drugs will be provided in an extra-legal manner? This is really my fundamental question here... did someone threaten to violate patents of the U.S. pharamaceutical industry as a nation?
Re: 3. Interesting (your comment on generics). Hadn't heard that before.
Re: Bottom line. Exactly. I'm told the same thing, and it offends me to no end that the risk/reward tends to overwhelmingly favor Amermican risk-taking companies, but at the expense of American consumers. Some of these countries have per-capita incomes almost equal to ours. It sounds entirely like a free-rider/strong-arm theft problem.
Hello
|
The risk/reward calculus is heavily skewed by the US R&D tax credit, which requires that both the bulk of R&D spending be allocated to the US and profits in the US be sufficiently high to justify the distorted allocation of development costs.
